Abbott Laboratories (ABT)

In the past six months, Abbott Laboratories reported its quarterly earnings on October 15, 2025, meeting analysts' consensus estimates of $1.30 EPS and reporting revenue of $11.37 billion. Several analysts have issued positive ratings and increased price targets for Abbott Laboratories. On August 29, 2025, Abbott declared its 407th consecutive quarterly dividend of $0.59 per share. Competition in medical devices may intensify pressure on Abbott's medical device segment. On August 8, 2025, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock.

Information specifically detailing the demand seasonality for Abbott Laboratories' products and services is not explicitly provided. The healthcare industry, in general, can experience some seasonality. Abbott's diversified portfolio helps to mitigate risks associated with reliance on any single product or market segment, potentially smoothing out overall demand fluctuations. The company's organic revenue growth averaged 6.2% year-on-year over the last two years, suggesting a relatively stable underlying demand for its core operations.

Abbott Laboratories is a multinational medical devices and healthcare company headquartered in Abbott Park, Illinois, operating within the healthcare sector. Its core businesses are structured into four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Abbott provides branded generic pharmaceuticals, primarily for sale outside the United States. It offers a wide array of diagnostic systems and tests, including products like BinaxNOW and the Alinity m HR HPV assay. Abbott manufactures pediatric and adult nutritional products such as Similac, Pedialyte, Ensure, Glucerna, and ZonePerfect, holding a significant market share in the infant formula industry. The company also develops medical devices across various areas, featuring products like FreeStyle Libre, i-STAT, and MitraClip.

Abbott Laboratories has a significant global presence, operating in over 160 countries and sourcing from at least 62 suppliers worldwide. North America, particularly the United States, holds the largest share of the infectious disease diagnostics market. Europe is a mature but growing market, with Germany, the UK, and France being major contributors. The Asia-Pacific (APAC) region is emerging as the fastest-growing market, driven by rising infectious disease burdens and expanding healthcare access in countries like China, India, South Korea, and Japan.

Abbott Laboratories maintains a strong brand reputation, often associated with innovation and a commitment to global health. Abbott's rapid development of COVID-19 diagnostic tests during the pandemic showcased its agility and commitment to public health. Abbott actively engages in partnerships and initiatives that enhance its brand image, such as the "We Give Blood" drive, the Abbott-Real Madrid partnership, and the sponsorship of the Abbott World Marathon Majors. In October 2025, Abbott and the Abbott Fund supported the Northern Illinois Food Bank with a $250,000 grant. Continuous investment in research and development strengthens its position in the healthcare sector.

Abbott Laboratories has a diversified ownership structure, with a significant portion held by institutional investors, accounting for 75.18% of the company's stock. Major institutional shareholders include Vanguard Group Inc., Wellington Management Group LLP, Goldman Sachs Group Inc., Massachusetts Financial Services Co. MA, and Charles Schwab Investment Management Inc. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its stake by 101.1% in the second quarter. Insiders own 0.46% of the company's stock.